Skip to main content
. 2018 Sep 6;13:2775–2784. doi: 10.2147/COPD.S175017

Figure 3.

Figure 3

Forest plots of studies comparing the pooled hazard ratio for time-to-first moderate/severe exacerbation in patients with COPD receiving ICS-containing treatment or non-ICS/ICS withdrawal/placebo treatments by subgroup.

Note: (A) Eosinophil counts <2% and (B) eosinophil counts ≥2%.

Abbreviation: ICS, inhaled corticosteroid.